# MANAGEMENT REVIEW AND MONITORING

## Header
 
|Item          |Details                                                                                                                 
|--------------|---------| 
|Purpose       |Ensure periodic review and assessment of the adequacy, suitability and effectiveness of the Quality Management System including identification of relevant actions in the event of undesirable trends, and detection of opportunities for continual improvement of processes and the system itself.| 
|Department    |Quality                                                                                                                
|Categorie     |GDP                                                                                                                    

## REFERENCES AND ASSOCIATED DOCUMENTS

### References
* [CAPA][YUISV]

## ROLES

Role     |   Description    |   Who
------   |   --------       |  ----
Requester  | Schedules the GDP Quality Management  | Quality Officer
Reviewer | Reviews agenda and records of meetings| Quality Officer
Responsible Person | Draft and circulate the minutes of the GDP Quality Management Review, and track the progress of CAPAs   | Quality Officer
Contributor | Compile and make available slides about Pharmacovigilance activities | Head of Pharmacovigilance

## PROCEDURE

### Preparation for GDP Quality Management Review Meeting
* Pharmacovigilance prepare information on key metrics for presentation. This will include: ICSR (individual Case Study Reports) compliance, review of PV deviations, safety reports and other key information.
* Key information and status on the following key metrics is collated by Quality Department, as applicable:
  * Distribution Complaints
  * Corrective and Preventative Actions (CAPA's)
  * SeIf-Inspection
  * Quality / Technical Agreements and Contractor Performance
  * Regulatory/Audit Findings
  * Regulatory Commitments
  * Risk Assessments
  * Training Status
  * Priorities for Quality including key areas of focus for immediate future i.e. 6 months.
* The presentation will also cover:
  * A review of action items from the last meeting.
  * Highlight any change, i.e. legislation, business, suppliers, or services, that has the potential to impact upon the QMS.
* The core team members for Quality Management Review meeting are:
  * Director of Quality
  * Chief Operations Officer
  * Chief Executive Officer
  * Chief Financial Officer
  * Responsible Person(s)
  * Head of Pharmacovigilance

### GDP Quality Management Review Meeting
* The leadership team and key personnel are invited to attend the meeting.
* Meeting minutes will document all actions that result from the review of the data presented and any changes in the business that could impact the QMS. All attendees will receive a copy of the minutes including the presentation(s) delivered.
* The Team determines whether the QMS is in a state of control and identifies:
  * Changes in the business environment and objectives that could affect the QMS.
  * Whether the resources involved in the delivery of the QMS are adequate.
  * Continuous improvements that could enhance the QMS. 
* Minutes of the QMR meeting are circulated following approval by the CEO (or designated deputy).
* The Quality Department documents CAPAâ€™s in the CAPA system.

## TRAINING
Anyone who performs the tasks as outlined in this procedure must first complete read and understand training.

[GMP Guidelines]: https://ec.europa.eu/health/documents/eudralex/vol-4_en]
[GDP Guidelines]: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:343:0001:0014:EN:PDF
[AMXWS]: /procedures/Procedure_GDP_AMXWS_Management_of_Standard_Operating_Procedures.md
[XIDEX]: /procedures/Procedure_GDP_XIDEX_Responsible_Person.md
[BWRPX]: /procedures/Procedure_GDP_BWRPX_Documentation_Control.md
[XCEUG]: /procedures/Procedure_GDP_XCEUG_Deviations.md
[UYNEF]: /procedures/Procedure_GDP_UYNEF_Change_Control.md
[OZCFN]: /procedures/Procedure_GDP_OZCFN_Management_Review_And_Monitoring.md
[LBHIY]: /procedures/Procedure_GDP_LBHIY_Quality_Risk_Management.md
[ZWJPR]: /procedures/Procedure_GDP_ZWJPR_Training.md
[VQICE]: /procedures/Procedure_GDP_VQICE_Receipt_Of_Medicinal_Products.md
[AGTXC]: /procedures/Procedure_GDP_AGTXC_Establishing_The_Authority_Of_Suppliers_To_Supply_Medicinal_Products.md
[ZIWKI]: /procedures/Procedure_GDP_ZIWKI_Customer_Complaints.md
[VOZWP]: /procedures/Procedure_GDP_VOZWP_Recall_Procedure.md
[HBQIN]: /procedures/Procedure_GDP_HBQIN_Outsourced_Activities.md
[GMQHI]: /procedures/Procedure_GDP_GMQHI_Self_Inspections.md
[VTOMR]: /procedures/Procedure_GDP_VTOMR_Falsified_Medicinal_Products.md
[BMAXZ]: /procedures/Procedure_GDP_BMAXZ_Medicinal_Product_Returns.md
[YUISV]: /procedures/Procedure_GDP_YUISV_CAPA.md
[QEAIC]: /procedures/Document_QEAIC_Glossary.md
[GGNHM]: /procedures/Procedure_GDP_GGNHM_Reporting_of_Adverse_Events.md
